The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure
Lütfü Aşkın, Okan Tanrıverdi
2022Bolu Abant Izzet Baysal Universitesi Tip Fakultesi Abant Tip Dergisi15 citationsDOIOpen Access PDF
Abstract
Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow. Development of natriuretic peptide (NP) through inhibition of the neprilysin enzyme is the therapeutic target in HF. Treatment with sacubitril/valsartan has been shown to significantly reduce mortality and hospitalization and rehospitalization rates for HF compared with enalapril. Sacubitril/valsartan may provide significant additional benefit in HF patients.
Topics & Concepts
SacubitrilSacubitril, ValsartanEnalaprilValsartanHeart failureNeprilysinEjection fractionCardiologyMedicineInternal medicineAngiotensin-converting enzymeBlood pressureEnzymeChemistryBiochemistryHeart Failure Treatment and ManagementCardiovascular Function and Risk FactorsDiabetes Treatment and Management